BRAF and melanoma: CB839 also improved OS of mice with intracranial xenografts of MEL624, a BRAF-mutant human melanoma cell line with High-OXPHOS and de novo resistance to MAPKi (median OS 31 vs 16 days; P = .0266; Figure 3H).9,15 No significant weight loss or toxicity was observed with CB839 treatment (Supplementary Figure S4), consistent with the favorable safety profile observed in patients.28